Interoperability in the spotlight at fall AAMI-FDA summit

Seeking to identify the key safety issues involved in medical-device interoperability, the Association for the Advancement of Medical Instrumentation (AAMI) and the FDA are organizing a summit on the subject.

The gathering, slated for Oct. 2 and 3 in Herndon, Va., also will provide a forum to discuss prioritizing interoperability activities and consider the general challenges faced by healthcare providers working to connect medical devices and networks.

Interoperability is difficult to achieve in healthcare because of the need to maintain patient safety as a priority at all times, AAMI President Mary Logan, JD, said in a statement.

“Consider just the challenges in making wireless technologies work for medical devices that monitor life-threatening conditions, deliver medication infusions, direct alarms to caregivers or sustain life,” she said, adding that the complexity of the interoperability challenge in healthcare is “mind boggling.”

AAMI said the format will resemble that of previous AAMI summits. Recent such events have facilitated discussions on alarms management, reprocessing reusable medical devices and infusion pumps.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.